Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

Unum’s leadership possesses biotech and large pharma drug development experience and deep scientific expertise in cancer immunotherapy.



Charles "Chuck" Wilson, PhD

Chief Executive Officer



Seth Ettenberg, PhD

Chief Scientific Officer



Geoffrey Hodge

Chief Technical Officer



Michael Vasconcelles, MD

Chief Medical Officer


Sara Saltzman
VP, Regulatory Affairs


Sara joined Unum in January 2019 and is responsible for the company’s regulatory affairs strategy and operations. Sara is an accomplished regulatory professional with more than 17 years of global regulatory and drug development experience across a variety of therapeutic areas. She has successfully led regulatory and cross-functional teams supporting development programs from first-in-human trials through commercialization, including global marketing approvals for Mozobil® (plerixafor) and Kanuma® (sebelipase alfa). Prior to Unum, Sara held leadership positions at Alexion, Synageva, Takeda Oncology, and Sanofi Genzyme. She received a Bachelor of Arts degree in Biology from Colby College.